Can we predict who will respond to melanoma immunotherapy?
NCT ID NCT07407166
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is tracking 40 people in Slovenia with metastatic melanoma who are receiving standard first-line immunotherapy. Researchers want to see how well the treatment works and look for clues in blood, stool, and tumor samples that might predict who will benefit most. The goal is to improve personalized treatment for advanced melanoma.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Immunotherapy (immune checkpoint inhibitors, such as anti-PD-1 with or without anti-CTLA-4)
What this could lead to
If successful, this could help doctors better predict which patients with metastatic melanoma will benefit from immunotherapy, leading to more personalized treatment plans.
What could go wrong
This is an observational study with only 40 participants, so results may not apply to everyone. It is not testing a new treatment, just gathering data on standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Oncology Ljubljana
RECRUITINGLjubljana, 1000, Slovenia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••